Karyopharm Therapeutics Stock News

Karyopharm Therapeutics reported their Q3 earnings with a beat on revenue and a slight miss on EPS. The company revealed that XPOVIO is making inroads into multiple myeloma.

Karyopharm Therapeutics reported their Q3 earnings with a beat on revenue and a slight miss on EPS. The company revealed that XPOVIO is making inroads into multiple myeloma. Despite the encouraging ea

Karyopharm Therapeutics Inc. (NASDAQ:KPTI)s stock price gapped up prior to trading on Thursday . The stock had previously closed at $6.69, but opened at $7.00. Karyopharm Therapeutics shares last traded at $6.86, with a volume of 4,606 shares. A number of research analysts have recently issued reports on the stock. JPMorgan Chase & Co. cut []

- Top-Line Study Results Expected by End of 2021 or Early 2022 -

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) traded at $7.27 at close of the session on Friday, 11/26/21, made a downward move of -5.58% on its previous days price. Looking at the stock we see that its previous close was $7.70 and the beta (5Y monthly) reads 0.20 with the days price range being $7.04 $7.66. In Investors Take Advantage Of -5.58% Loss In Karyopharm Therapeutics Inc. (NASDAQ: KPTI) Read More »

Investors need to pay close attention to Karyopharm (KPTI) stock based on the movements in the options market lately.

Investors need to pay close attention to Karyopharm (KPTI) stock based on the movements in the options market lately.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has been given an average rating of Hold by the eight ratings firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and three have assigned a buy recommendation to the company. The average []

During the last session, Karyopharm Therapeutics Inc. (NASDAQ:KPTI)s traded shares were 1.03 million, with the beta value of the company hitting 0.06. At the end of the trading day, the stocks price was $7.70, reflecting an intraday gain of 0.13% or $0.01. The 52-week high for the KPTI share is $18.00, that puts it down We Just Learned Something New! After Karyopharm Therapeutics Inc. (NASDAQ: KPTI)s -7.12% Loss This Week Read More »

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shares were down 4.1% during trading on Tuesday . The stock traded as low as $7.24 and last traded at $7.24. Approximately 3,947 shares were traded during mid-day trading, a decline of 100% from the average daily volume of 1,949,599 shares. The stock had previously closed at $7.55. KPTI has been […]

Charles Schwab Investment Management Inc. boosted its holdings in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 2.8% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 465,058 shares of the companys stock after purchasing an additional 12,814 shares during the quarter. Charles Schwab Investment Management Inc.s holdings in Karyopharm Therapeutics were worth $4,800,000 as of its []

Karyopharm Therapeutics (NASDAQ:KPTI) was downgraded by stock analysts at Morgan Stanley from an “overweight” rating to an “equal weight” rating in a report released on Friday, Analyst Ratings Network reports. They presently have a $10.00 target price on the stock, down from their prior target price of $27.00. Morgan Stanley’s price target indicates a potential […]